Carlos Morel é nomeado presidente do Conselho de Administração da TB Alliance
A Aliança Global para o Desenvolvimento de drogas para a tuberculose anunciou a nomeação do Dr. Carlos Morel para o cargo de presidente de seu Conselho de Administração. O Dr. Morel é diretor do Centro de Desenvolvimento Tecnológico em Saúde (CDTS) da Fundação Oswaldo Cruz (FIOCRUZ), uma instituição científica dedicada à saúde pública, pesquisa, biomédica e desenvolvimento, localizada no Brasil, um país com elevada carga de TB. A TB Alliance é uma organização sem fins lucrativos, que procura melhores, mais rápidos e acessíveis métodos para a cura da tuberculose, doença frequentemente considerada como uma doença do passado, mas que ainda é uma das principais causas mundiais de morte, matando 1,4 milhões de pessoas a cada ano. O tratamento da tuberculose leva 6-30 meses para a cura de doentes e, por causa das dificuldades em implantar seu complexo regime, o abandono está causando o desenvolvimento de formas cada vez mais resistentes e mortais dessa doença.
TB Alliance Announces New Chair and Vice-Chair of Board of Directors
Dr. Carlos Morel appointed as Chair; Dr. Jaap Broekmans appointed as Vice-Chair
TB Alliance also announces the appointment of Dr. Jaap F. Broekmans as Vice-Chairman of its Board of Directors. Dr. Broekmans is currently Chair of WHO’s Global Task Force on TB Impact Measurement (since 2007) and Adjunct Professor, Epidemiology, at the Johns Hopkins Bloomberg School of Public Health. From 1987-2005, he was the Executive Director of KNCV Tuberculosis Foundation. He also served as the co-founder and inaugural vice-chair of the STOP TB Partnership and as the first Chairman of STAG-TB, WHO’s strategic technical advisory group on TB. He has served on the TB Alliance’s Board since 2009.
“I’m so pleased to serve as Chairman of TB Alliance, which I helped start more than a decade ago,” says Dr. Morel. “I step into this role at a critical time in the organization’s evolution, where it faces unprecedented success in the development of its pipeline and is poised to deliver improved TB treatments.”
Dr. Morel served as the TB Alliance’s first Chairman in 2000, and succeeds Dr. Bruce Carter, CEO of Immune Design, who completed his Board term limit. Dr. Morel has subsequently served additional terms on the TB Alliance Board of Directors, joining again in 2010. As a leader in neglected disease research and development, Dr. Morel brings significant experience to his post.
“We welcome this new leadership-both Dr. Morel and Dr. Broekmans are pioneers in the fields of TB and public health,” said Dr. Mel Spigelman, President and CEO, TB Alliance. “Their experience will be invaluable as we advance our mission from developing improved TB regimens to delivering them to those in need.”
TB Alliance would like to thank Dr. Bruce Carter for his dedication and excellence in serving the organization. Dr. Carter will continue to serve as an advisor to the organization.